SG10201608904YA - Self-Stabilizing Linker Conjugates - Google Patents

Self-Stabilizing Linker Conjugates

Info

Publication number
SG10201608904YA
SG10201608904YA SG10201608904YA SG10201608904YA SG10201608904YA SG 10201608904Y A SG10201608904Y A SG 10201608904YA SG 10201608904Y A SG10201608904Y A SG 10201608904YA SG 10201608904Y A SG10201608904Y A SG 10201608904YA SG 10201608904Y A SG10201608904Y A SG 10201608904YA
Authority
SG
Singapore
Prior art keywords
self
linker conjugates
stabilizing linker
stabilizing
conjugates
Prior art date
Application number
SG10201608904YA
Other languages
English (en)
Inventor
Lyon Robert
Doronina Svetlana
Bovee Timothy
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/799,244 external-priority patent/US9504756B2/en
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG10201608904YA publication Critical patent/SG10201608904YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Insulating Materials (AREA)
  • External Artificial Organs (AREA)
  • Pyrrole Compounds (AREA)
SG10201608904YA 2012-05-15 2013-05-14 Self-Stabilizing Linker Conjugates SG10201608904YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261647373P 2012-05-15 2012-05-15
US201361770983P 2013-02-28 2013-02-28
US201361773067P 2013-03-05 2013-03-05
US13/799,244 US9504756B2 (en) 2012-05-15 2013-03-13 Self-stabilizing linker conjugates

Publications (1)

Publication Number Publication Date
SG10201608904YA true SG10201608904YA (en) 2016-12-29

Family

ID=49584442

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201608904YA SG10201608904YA (en) 2012-05-15 2013-05-14 Self-Stabilizing Linker Conjugates
SG11201406252WA SG11201406252WA (en) 2012-05-15 2013-05-14 Self-stabilizing linker conjugates

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201406252WA SG11201406252WA (en) 2012-05-15 2013-05-14 Self-stabilizing linker conjugates

Country Status (14)

Country Link
EP (1) EP2850094B1 (fr)
JP (5) JP6423340B2 (fr)
KR (5) KR102144069B1 (fr)
CN (2) CN108465112B (fr)
AU (5) AU2013263002C1 (fr)
BR (1) BR112014028222A2 (fr)
CA (2) CA2869777C (fr)
EA (1) EA037203B1 (fr)
HK (1) HK1207388A1 (fr)
MX (2) MX368678B (fr)
NZ (3) NZ741211A (fr)
SG (2) SG10201608904YA (fr)
WO (1) WO2013173337A2 (fr)
ZA (1) ZA201407369B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013031819B1 (pt) 2011-06-10 2022-05-03 Mersana Therapeutics, Inc Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2859755C (fr) 2011-12-23 2021-04-20 Pfizer Inc. Regions constantes d'anticorps modifies pour conjugaison specifique a un site, et leurs procedes et utilisations
NZ741211A (en) * 2012-05-15 2019-09-27 Seattle Genetics Inc Self-stabilizing linker conjugates
MX367851B (es) 2013-10-11 2019-09-09 Mersana Therapeutics Inc Conjugados de proteína-polímero-fármaco.
CN105813655B (zh) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 蛋白-聚合物-药物缀合物
KR102645430B1 (ko) 2013-10-15 2024-03-11 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
JP6701077B2 (ja) 2013-12-19 2020-05-27 シアトル ジェネティックス， インコーポレイテッド 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
WO2016008112A1 (fr) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Lieurs et application à des conjugués anticorps-médicament (acd) associée
SG11201701311YA (en) * 2014-09-11 2017-03-30 Seattle Genetics Inc Targeted delivery of tertiary amine-containing drug substances
RU2715905C2 (ru) * 2014-10-01 2020-03-04 МЕДИММЬЮН, ЭлЭлСи Способ конъюгации полипептида
WO2016063959A1 (fr) 2014-10-24 2016-04-28 日油株式会社 Complexe anticorps-médicament comprenant un lieur de type benzylidène acétal cyclique
JP6752204B2 (ja) * 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
CN111620862A (zh) * 2014-12-09 2020-09-04 艾伯维公司 Bcl-xl抑制性化合物和包括其的抗体药物缀合物
RU2020123953A (ru) * 2014-12-09 2020-09-18 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их
SG11201706786UA (en) * 2015-03-18 2017-09-28 Seattle Genetics Inc Cd48 antibodies and conjugates thereof
CN106267225B (zh) 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
CN106380508A (zh) * 2015-07-28 2017-02-08 上海皓元生物医药科技有限公司 一种抗体偶联药物连接子的工业化生产方法
TWI726942B (zh) 2015-11-30 2021-05-11 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
TWI814699B (zh) 2015-12-04 2023-09-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
MA43835A (fr) 2016-03-25 2018-11-28 Seattle Genetics Inc Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
EP3442979A4 (fr) * 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey Poisons de topoisomérase
WO2017196598A1 (fr) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Conjugués anticorps-médicaments d'analogues de la tubulysine à stabilité améliorée
CN109563168A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
EP3468615A1 (fr) 2016-06-08 2019-04-17 AbbVie Inc. Conjugué médicament-anticorps anti-egfr
CA3027181A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Conjugues medicament-anticorps anti-egfr
CN109562169A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
CA3027046A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-cd98 et conjugues anticorps-medicament
RU2764651C2 (ru) 2016-06-08 2022-01-19 Эббви Инк. Антитела к в7-н3 и конъюгаты антитела и лекарственного средства
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
EP3468596A2 (fr) 2016-06-08 2019-04-17 AbbVie Inc. Anticorps anti-cd98 et conjugués anticorps-médicament
SG11201900699QA (en) * 2016-08-09 2019-02-27 Seattle Genetics Inc Drug conjugates with self-stabilizing linkers having improved physiochemical properties
KR20240000650A (ko) 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
AU2017383142A1 (en) 2016-12-22 2019-07-04 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
CN107652219B (zh) * 2017-08-14 2021-06-08 上海新理念生物医药科技有限公司 四马来酰亚胺型连接子及其应用
BR112020004495A2 (pt) 2017-09-08 2020-09-08 Seattle Genetics, Inc. composto, composição, e, método para preparar uma composição.
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
WO2019234136A1 (fr) 2018-06-05 2019-12-12 King's College London Constructions de ciblage btnl3/8 pour l'administration de charges utiles au système gastro-intestinal
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
CN113766933A (zh) * 2019-06-28 2021-12-07 上海复旦张江生物医药股份有限公司 一种抗体偶联药物、其中间体、制备方法及应用
EP4037717A1 (fr) 2019-10-04 2022-08-10 Seagen Inc. Conjugués peptidiques de camptothécine
WO2021226454A1 (fr) * 2020-05-08 2021-11-11 Mpeg La, L.L.C. Composés de liaison
WO2022068898A1 (fr) * 2020-09-29 2022-04-07 迈威(上海)生物科技股份有限公司 Procédé de préparation d'un conjugué anticorps-médicament de pontage bis-substitué
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023033129A1 (fr) 2021-09-03 2023-03-09 東レ株式会社 Composition pharmaceutique pour le traitement et/ou la prévention du cancer
WO2023178289A2 (fr) 2022-03-17 2023-09-21 Seagen Inc. Conjugués de camptothécine
EP4321522A1 (fr) 2022-08-12 2024-02-14 Seagen Inc. Composés cytotoxiques et conjugués de ceux-ci
WO2024092219A1 (fr) * 2022-10-28 2024-05-02 Eli Lilly And Company Maléimides à autohydrolyse pour bioconjugaison

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1994001485A1 (fr) * 1992-07-01 1994-01-20 Akzo Nobel N.V. Procede de modification de compositions de resine d'ether de polyphenylene
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
PT871490E (pt) 1995-12-22 2003-07-31 Bristol Myers Squibb Co Ligantes de hidrazona ramificada
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US5973166A (en) 1998-03-02 1999-10-26 The Dexter Corporation Method for the preparation of maleimides
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP2357006B1 (fr) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Conjugués de médicaments et leur utilisation pour traiter le cancer, maladie auto-immune ou maladie infectieuse
US7432331B2 (en) * 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP3120861B1 (fr) 2003-11-06 2018-08-15 Seattle Genetics, Inc. Composés intermédiaires pour la préparation de conjugués d'auristatin avec des éléments de liaison
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
CA2564076C (fr) 2004-05-19 2014-02-18 Medarex, Inc. Bras de liaison chimiques et conjugues associes
CN102973947A (zh) 2004-06-01 2013-03-20 健泰科生物技术公司 抗体-药物偶联物和方法
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
WO2007008603A1 (fr) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Composes de monomethylvaline presentant des modifications de la chaine laterale de phenylalanine au niveau de l'extremite c
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
ES2374964T3 (es) 2006-01-25 2012-02-23 Sanofi Agentes citotóxicos que comprenden nuevos derivados de tomaimicina.
CA2702555A1 (fr) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Agents de liaison au cd19 et utilisations de ceux-ci
ES2647927T3 (es) 2008-03-18 2017-12-27 Seattle Genetics, Inc. Conjugados enlazadores del fármaco auriestatina
MX2010011807A (es) 2008-04-30 2011-03-04 Immunogen Inc Entrelazadores y sus usos.
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
WO2010091150A1 (fr) 2009-02-05 2010-08-12 Immunogen, Inc. Nouveaux dérivés de benzodiazépine
CN102448494B (zh) * 2009-02-13 2016-02-03 免疫医疗公司 具有胞内可裂解的键的免疫共轭物
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
CA2815363C (fr) * 2010-10-22 2020-07-14 Seattle Genetics, Inc. Effets synergiques entre des conjugues d'anticorps et de medicament a base d'auristatine et des inhibiteurs de la voie pi3k-akt-mtor
EP3053600B1 (fr) 2011-02-15 2020-01-29 ImmunoGen, Inc. Dérivés de benzodiazépine cytotoxique
NZ741211A (en) 2012-05-15 2019-09-27 Seattle Genetics Inc Self-stabilizing linker conjugates
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート

Also Published As

Publication number Publication date
WO2013173337A3 (fr) 2015-06-11
NZ630870A (en) 2016-10-28
EA037203B1 (ru) 2021-02-18
NZ724892A (en) 2018-04-27
SG11201406252WA (en) 2014-10-30
CN104822656A (zh) 2015-08-05
CN104822656B (zh) 2018-05-01
MX2014013807A (es) 2015-02-04
KR20220166877A (ko) 2022-12-19
KR20200097000A (ko) 2020-08-14
JP2022044690A (ja) 2022-03-17
KR102433686B1 (ko) 2022-08-19
AU2013263002A1 (en) 2014-09-25
AU2021201636A1 (en) 2021-04-08
AU2013263002C1 (en) 2018-05-31
KR102557309B1 (ko) 2023-07-20
JP2020122023A (ja) 2020-08-13
ZA201407369B (en) 2020-02-26
KR20230113821A (ko) 2023-08-01
AU2018201190B2 (en) 2020-01-30
EP2850094A4 (fr) 2016-07-06
AU2013263002B2 (en) 2017-11-30
EP2850094B1 (fr) 2024-04-17
EP2850094A2 (fr) 2015-03-25
JP2015521187A (ja) 2015-07-27
JP7014856B2 (ja) 2022-02-01
JP2018162251A (ja) 2018-10-18
JP6709247B2 (ja) 2020-06-10
KR102475777B1 (ko) 2022-12-09
KR20150009991A (ko) 2015-01-27
CA3131619A1 (en) 2013-11-21
AU2021201636B2 (en) 2023-02-16
WO2013173337A2 (fr) 2013-11-21
JP7431261B2 (ja) 2024-02-14
NZ741211A (en) 2019-09-27
CN108465112A (zh) 2018-08-31
AU2020202805B2 (en) 2020-12-17
CN108465112B (zh) 2022-04-29
JP6423340B2 (ja) 2018-11-14
CA2869777C (fr) 2021-11-16
AU2018201190A1 (en) 2018-03-08
HK1207388A1 (en) 2016-01-29
KR102144069B1 (ko) 2020-08-13
AU2023203005A1 (en) 2023-06-01
MX368678B (es) 2019-10-11
JP2024032941A (ja) 2024-03-12
BR112014028222A2 (pt) 2017-06-27
EA201401254A1 (ru) 2015-09-30
KR20210094150A (ko) 2021-07-28
MX2019012201A (es) 2019-11-28
AU2020202805A1 (en) 2020-05-21
CA2869777A1 (fr) 2013-11-21

Similar Documents

Publication Publication Date Title
HUS2300020I1 (hu) Pirrolobenzodiazepin-antitest konjugátumok
HK1207388A1 (en) Self-stabilizing linker conjugates
IL268420A (en) Oligonucleotide conjugates
HRP20180870T1 (hr) Antitijelo-lijek konjugat
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
ZA201501996B (en) Drug-protein conjugates
IL237672B (en) Drug-protein conjugates
IL233701A0 (en) Conjugates of a binding molecule
ZA201409119B (en) Polymer-nsaid conjugate
EP2836238A4 (fr) Conjugués de copolymère